FDA approved Merck & Co. Inc.’s Zinplava (bezlotoxumab) with a limited indication to reduce recurrence of Clostridium difficile in patients 18 years or older who are receiving antibacterial drug treatment for C. difficile infection and are at high risk for recurrence.
The labeling states that Zinplava is not indicated for the treatment of C. difficile infection (CDI) and specifies that the...





